Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 602-610

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Fogari, Elena ^a   Salvadeo, Sibilla ^a   Gravina, Alessia ^a   Ferrari, Ilaria ^a   Fassi, Raffaella ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

hypertension; irbesartan; moxonidine; type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOXONIDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE METABOLISM; HEADACHE; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN SENSITIVITY; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN SENSITIVITY; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; XEROSTOMIA;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMIDAZOLES; LIPIDS; MALE; MIDDLE AGED; RECEPTORS, DRUG; TETRAZOLES;

EID: 34347407848     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.03.015     Document Type: Article

References (38)

1. McInnes G.T. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl 23 (2005) S3-S8
2. Manrique C.M., Lastra G., Palmer J., et al. Hypertensiona treatable component of the cardiometabolic syndrome: Challenges for the primary care physician. J Clin Hypertens (Greenwich) 8 Suppl 1 (2006) 12-20
3. O'Shaughnessy I.M., and Kotchen T.A. Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance. Curr Opin Cardiol 8 (1993) 757-764
4. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
5. Bonora E., Kiechl S., Willeit J., et al., Bruneck Study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck study. Diabetes Care 26 (2003) 1251-1257
6. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 346 (2002) 393-403
7. Montani J.P., Antic V., Yang Z., and Dulloo A. Pathways from obesity to hypertension: From the perspective of a vicious triangle. Int J Obes Relat Metab Disord 26 Suppl 2 (2002) S28-S38
8. Ernsberger P., Koletsky R.J., and Friedman J.E. Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease. Rev Contemp Pharmacother 9 (1998) 411-428
9. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 24 Suppl 1 (2001) 21-24
10. Guidelines Subcommittee. 1999 World Health OrganizationInternational Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17 (1999) 151-183
11. Mogensen C.E., Keane W.F., Bennett P.H., et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346 (1995) 1080-1084
12. Steiness I. Vibratory perception in diabetics during arrested blood flow to the limb. Acta Med Scand 163 (1959) 195-205
13. In: Bankowski Z. (Ed). International Ethical Guidelines for Biomedical Research Involving Human Subjects (1993), Council for International Organizations of Medical Sciences, Geneva, Switzerland
14. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 24 Suppl 1 (2001) S44-S47
15. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
16. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8 (1972) 260-266
17. Bunn H.F., Gabbay K.H., and Gallop P.M. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 200 (1978) 21-27
18. [in German]. Borner K., and Klose S. Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 15 (1978) 121-130
19. Wahlefeld A.W. Triglycerides: Determination after enzymatic hydrolysis. In: Bermeyer H.U. (Ed). Methods of Enzymatic Analysis. 2nd ed. (1974), Academic Press, New York, NY 18-31
20. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
21. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
22. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
23. Winer B.J. Statistical Principles in Experimental Design. 2nd ed. (1971), McGraw-Hill, New York, NY
24. Messerli F. Moxonidine: A new and versatile anti hypertensive. J Cardiovasc Pharmacol 35 Suppl 4 (2000) S53-S56
25. Schachter M. Metabolic effects of moxonidine and other centrally acting anti hypertensives. Diabetes Obes Metab 1 (1999) 317-322
26. Ernsberger P., Ishizuka T., Liu S., et al. Mechanisms of anti hyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288 (1999) 139-147
27. Yakubu-Madus F.E., Johnson W.T., Zimmerman K.M., et al. Metabolic and hemodynamic effects of mox onidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 48 (1999) 1093-1100
28. Ernsberger P., Koletsky R.J., Collins L.A., and Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 10 Suppl 1 (1996) 275-282
29. Henriksen E.J., Jacob S., Fogt D.L., et al. Anti hypertensive agent moxonidine enhances muscle glucose trans port in insulin-resistant rats. Hypertension 30 (1997) 1560-1565
30. Haenni A., and Lithell H. Moxonidine improves insulin sensitivity in insulinresistant hypertensives. J Hypertens Suppl 17 (1999) S29-S35
31. Lumb P.J., McMahon Z., Chik G., and Wierzbicki A.S. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 58 (2004) 465-468
32. Abstract 28.6. Almazov V., Shlyakhto E., Yv B., et al. Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy. J Hypertens 18 Suppl 2 (2000) S12
33. Chazova I., Almazov V.A., and Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, over weight patients: A comparison with metformin. Diabetes Obes Metab 8 (2006) 456-465
34. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
35. Derosa G., Cicero A.F., Gaddi A., et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol 45 (2005) 599-604
36. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive sum mary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
37. American Diabetes Association. Standards of medical care in diabetes 2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
38. Williams B., Poulter N.R., Brown M.J., et al., British Hypertension Society. Guidelines for management of hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185